There are two main reasons why CFDA deprives Cordyceps sinensis of its status as a health care product. First, the content of heavy metal arsenic in Cordyceps sinensis, Cordyceps sinensis powder and pure powder products is 4.4-9.9mg/kg, which seriously exceeds the standard (4- 10 times); Second, most of the scientific research achievements on the health care function of Cordyceps sinensis are made by domestic institutions, and the research level is basically at the level of "component identification". No high-quality research can prove that Cordyceps sinensis has a special effect on human health.
But this does not mean that Cordyceps sinensis has no medicinal value. Because of its medicinal value, CFDA kicked it out of the circle of health care products, but retained its identity as a medicinal material.
If measured by the records of ancient books, it seems that Cordyceps sinensis has medicinal efficacy, but its efficacy as a health care product is not recorded. The Supplementary Provisions on the Administration of Registration of Traditional Chinese Medicine gives the requirement of "meeting the requirements recorded in ancient books without providing clinical trial results and data", and does not mention other single traditional Chinese medicines.
Therefore, CFDA emphasizes that Cordyceps sinensis must provide evidence that it has special effects on human health, indicating that CFDA has finally begun to modernize the curative effect of traditional Chinese medicine, whether it is treatment or health care, and tends to use scientific experiments to test the actual curative effect of traditional Chinese medicine. This is undoubtedly a good thing for the development of Chinese medicine. From the point of view of public health, this is more favorable.